Different from chemotherapy, patients with RET fusion NSCLC have been unable to benefit well from MKI and ICI, and the same outcomes were shown in this study, though MKIs including cabozantinib and vandetanib were recommended in clinical guidelines (17–20). This evidence concerns the gene RET and non-small cell lung carcinoma.